Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates [Sugar (Dextrose)], Inorganic Chemicals), Functionality (Fillers, Diluents, Coating, Disintegrants), Formulation (Tablet, Capsule, Topical, Parenteral) - Global Forecast to 2026

世界の医薬品添加剤市場予測:製品別、機能性別、製剤別

◆タイトル:Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates [Sugar (Dextrose)], Inorganic Chemicals), Functionality (Fillers, Diluents, Coating, Disintegrants), Formulation (Tablet, Capsule, Topical, Parenteral) - Global Forecast to 2026
◆商品コード:PH3047
◆調査・発行会社:MarketsandMarkets
◆発行日:2021年3月18日
◆ページ数:295
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は、世界の医薬品添加剤市場規模が2021年79億ドルから2026年106億ドルまで、年平均5.8%成長すると予測しています。本調査資料では、医薬品添加剤の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業洞察、製品別(有機化学物質、無機化学物質、その他)分析、機能性別(充填剤・希釈剤、懸濁剤・粘度剤、コーティング剤、結合剤、香料・甘味料)分析、製剤別(経口製剤、局所製剤、非経口製剤、その他)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・産業洞察
・世界の医薬品添加剤市場規模:製品別(有機化学物質、無機化学物質、その他)
・世界の医薬品添加剤市場規模:機能性別(充填剤・希釈剤、懸濁剤・粘度剤、コーティング剤、結合剤、香料・甘味料)
・世界の医薬品添加剤市場規模:製剤別(経口製剤、局所製剤、非経口製剤、その他)
・世界の医薬品添加剤市場規模:地域別
・競争状況
・企業情報

“The pharmaceutical excipeints market is projected to reach USD 10.6 billion by 2026 from USD 7.9 billion in 2021, at a CAGR of 5.8%. ”
The rising global demand for pharmaceuticals has fueled the growth of drug production, increasing the excipient consumption rate. The discovery of increasingly lipophilic APIs, macromolecules, and biological actives has created the need for well-evaluated excipients and the development of new ones. The currently used excipients may not be sufficient to support the newly discovered actives. As a result, demand has grown for newer, improved drugs, which calls for the development of new drug delivery systems that can deal with the challenges of drug development, such as bioavailability, permeability, and poor solubility. These challenges can be addressed through functional excipients for manufacturing drugs, fueling the demand for pharmaceutical excipients.

“Based on product, the organic chemicals segment holds the largest market share during the forecast period. ”
Based on product, the pharmaceutical excipients market is segmented into three major categories— organic chemicals, inorganic chemicals, and other chemicals. In 2020, the organic chemicals segment accounted for the largest market share. This segment is also projected to register the highest CAGR during the forecast period. In 2020, the organic chemicals segment accounted for the largest share of the pharmaceutical excipients market. The large share of this segment can be attributed to the use of these chemicals in a majority of pharmaceutical formulations.

“Based on functionality, the fillers & dilluents is expected to have significant market size during the forecast period. ”
Based on functionality, pharmaceutical excipients are categorized into fillers & diluents, binders,
suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disintegrants,
lubricants & glidants, preservatives, emulsifying agents, and other functionalities. By functionality, fillers & diluents held the largest share in 2020. The demand for fillers and diluents is high as they are utilized in manufacturing tablets and capsules.

“Based on formualtions, the oral formulations segment holds the largest market share during the forecast period. ”
Based on the formulation, the pharmaceutical excipients market is segmented into oral, topical,
parenteral, and other formulations. Oral formulations dominate this market due to their wide usage and
efficacy against many ailments. Healthcare professionals recommended antiviral drugs as the primary line of defense against COVID-19. Due to their effectiveness in resolving pneumonia and respiratory ailments caused by the virus, these drugs were prescribed in large numbers. Since they are produced in tablet form for oral consumption, the oral formulations market has received a significant boost.

“Europe is expected to account for the largest share of the pharmaceutical excipeints market in 2020”
In 2020, Europe accounted for the largest share of the pharmaceutical excipients market, followed by North America, the Asia Pacific, Latin America, and the Middle East & Africa. Many European countries are focusing their attention on the generics market due to the expiration of blockbuster drug patents in the coming years. As a result, the European region is expected to witness major growth in its generics market during the forecast period, which will propel the demand for pharmaceutical excipients. Increasing government initiatives in countries such as Germany, Italy, and Spain for reducing drug prices are expected to drive the market for generic drugs in these countries. The abovementioned factors, alongside increasing investments for the development of biologics and advanced dosage forms, will increase the demand for novel excipients and thereby aid the growth of the pharmaceutical excipients market in Europe.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the Pharmaceutical excipients market
The key players operating in the pharmaceutical excipeints market include Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), and Croda International (UK). Other players in this market are Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France).

Research Coverage:
The report analyzes the pharmaceutical excipients market and aims at estimating the market size and future growth potential of this market based on various segments such as product, functionality, formulations, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global pharmaceutical excipients market. The report analyzes this market by product, functionality and formulations
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global pharmaceutical excipients market
• Market Development: Comprehensive information on the lucrative emerging markets by product, functionality, formulations, and end user
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global pharmaceutical excipients market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global pharmaceutical excipients market.

【レポートの目次】

1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.2.1 INCLUSIONS AND EXCLUSIONS 35
1.3 MARKET SCOPE 36
1.3.1 MARKETS COVERED 36
FIGURE 1 PHARMACEUTICAL EXCIPIENTS MARKET 36
1.3.2 YEARS CONSIDERED FOR THE STUDY 37
1.4 CURRENCY 37
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH APPROACH 39
FIGURE 2 RESEARCH DESIGN 39
2.1.1 SECONDARY RESEARCH 40
2.1.1.1 Key data from secondary sources 40
2.1.2 PRIMARY RESEARCH 41
2.1.2.1 Key data from primary sources 41
2.1.2.2 Breakdown of primaries 42
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 42
2.2 MARKET SIZE ESTIMATION 42
FIGURE 4 BOTTOM-UP APPROACH 43
FIGURE 5 TOP-DOWN APPROACH 43
FIGURE 6 REVENUE SHARE ANALYSIS 43
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE PHARMACEUTICAL EXCIPIENTS MARKET 44
FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES OF THE PHARMACEUTICAL EXCIPIENTS INDUSTRY (2020-2026) 45
2.3 DATA TRIANGULATION APPROACH 46
FIGURE 9 DATA TRIANGULATION METHODOLOGY 46
2.4 MARKET SHARE ESTIMATION 47
2.5 ASSUMPTIONS FOR THE STUDY 47
2.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 48
FIGURE 10 CRITERIA IMPACTING THE GLOBAL ECONOMY 49
FIGURE 11 SCENARIOS FOR THE RECOVERY OF THE GLOBAL ECONOMY 50

3 EXECUTIVE SUMMARY 51
FIGURE 12 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 51
FIGURE 13 ORGANIC CHEMICALS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 52
FIGURE 14 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2021 VS. 2026 (USD MILLION) 52
FIGURE 15 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2021 VS. 2026 (USD MILLION) 53
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL EXCIPIENTS MARKET 53
4 PREMIUM INSIGHTS 55
4.1 PHARMACEUTICAL EXCIPIENTS: MARKET OVERVIEW 55
FIGURE 17 GROWING PHARMACEUTICALS INDUSTRY COUPLED WITH ADVANCEMENTS IN FUNCTIONAL EXCIPIENTS ARE KEY FACTORS DRIVING MARKET GROWTH 55
4.2 PHARMACEUTICAL EXCIPIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
FIGURE 18 ASIA PACIFIC COUNTRIES TO SHOW THE HIGHEST GROWTH DURING THE FORECAST PERIOD 56
4.3 REGIONAL MIX: PHARMACEUTICAL EXCIPIENTS MARKET (2021–2026) 57
FIGURE 19 EUROPE TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD (2021–2026) 57
4.4 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY FORMULATION AND COUNTRY (2020) 58
FIGURE 20 ORAL FORMULATIONS ACCOUNTED FOR THE LARGEST SHARE OF
THE ASIA PACIFIC MARKET IN 2020 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
FIGURE 21 PHARMACEUTICAL EXCIPIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 59
5.2.1 MARKET DRIVERS 60
5.2.1.1 Growth of the pharmaceuticals market backed by functional excipients 60
FIGURE 22 GLOBAL PHARMACEUTICAL DRUG SALES (2008–2022) 60
5.2.1.2 Surge in the generics market 61
TABLE 1 DRUG PATENT EXPIRY, BY YEAR 61
5.2.1.3 Increasing uptake of biopharmaceuticals 62
5.2.1.4 Rising adoption of orphan drugs 62
FIGURE 23 INCREASING PENETRATION OF ORPHAN DRUGS (2010–2024) 63
FIGURE 24 RISING NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US 63
TABLE 2 KEY MARKET DRIVERS: IMPACT ANALYSIS 64
5.2.2 MARKET RESTRAINTS 64
5.2.2.1 Cost and time-intensive drug development process 64
5.2.2.2 Increasing regulatory stringency 64

TABLE 3 KEY MARKET RESTRAINTS: IMPACT ANALYSIS 65
5.2.3 MARKET OPPORTUNITIES 66
5.2.3.1 Multifunctional excipients 66
TABLE 4 MULTIFUNCTIONAL EXCIPIENTS 66
5.2.3.2 Shifting focus of pharmaceutical manufacturing to emerging countries 67
5.2.3.3 Growth in the biosimilars market 67
FIGURE 25 TOTAL NUMBER OF NEW MOLECULAR ENTITY (NME) & NEW BIOLOGIC LICENSE APPLICATION (BLA) FILINGS AND APPROVALS IN THE US,
2006–2018 68
TABLE 5 CLINICAL STUDIES FOR BIOLOGICS & BIOSIMILARS (2017) 69
TABLE 6 KEY MARKET OPPORTUNITIES: IMPACT ANALYSIS 69
5.2.4 MARKET CHALLENGES 69
5.2.4.1 Safety and quality concerns 69
5.2.4.2 Changing trade policies 70
TABLE 7 KEY MARKET CHALLENGES: IMPACT ANALYSIS 70
5.3 COVID-19 IMPACT 70
FIGURE 26 INCREASE IN REVENUE, BY QUARTER 71
FIGURE 27 COVID-19 IMPACT ON SECTIONS OF THE PHARMACEUTICAL INDUSTRY 71
6 INDUSTRY INSIGHTS 72
6.1 INTRODUCTION 72
6.2 INDUSTRY TRENDS 72
FIGURE 28 INCREASING FOCUS ON CO-PROCESSED EXCIPIENTS AND USE OF NANOTECHNOLOGY ARE THE LEADING TRENDS IN THE INDUSTRY 72
6.2.1 RISING DEMAND FOR CO-PROCESSED EXCIPIENTS 73
TABLE 8 MARKETED CO-PROCESSED EXCIPIENTS 74
6.2.2 IMPROVING EXCIPIENT CAPABILITIES USING NANOTECHNOLOGY 74
6.2.3 INCREASING USE OF DIRECT COMPRESSION IN ORAL DOSAGE FORMULATIONS 75
6.2.4 PHARMACEUTICAL EXCIPIENTS INFLUENCING THE COST OF PRODUCTION 76
6.3 REGULATORY ANALYSIS 76
6.3.1 NORTH AMERICA 76
6.3.1.1 US 76
6.3.1.2 Canada 77
6.3.2 EUROPE 78
6.3.3 ASIA PACIFIC 79
6.3.3.1 Japan 79
6.3.3.2 China 79
6.3.3.3 India 80
6.4 PORTER’S ANALYSIS 81
TABLE 9 PORTER’S FIVE FORCES ANALYSIS 81
6.4.1 INTENSITY OF COMPETITIVE RIVALRY 81
6.4.2 BARGAINING POWER OF SUPPLIERS 81
6.4.3 BARGAINING POWER OF BUYERS 81
6.4.4 THREAT OF SUBSTITUTES 81
6.4.5 INTENSITY OF NEW ENTRANTS 81
6.5 ECOSYSTEM ANALYSIS 82
6.6 PATENT ANALYSIS 82
FIGURE 29 PATENT ANALYSIS: NUMBER OF PUBLICATIONS FOR THE PHARMACEUTICAL INDUSTRY 83
TABLE 10 PROMINENT PHARMACEUTICAL EXCIPIENT PATENTS 83
6.7 TRADE DATA 84
6.8 PRICING ANALYSIS 86
6.8.1 US 86
6.8.2 CHINA 87
6.8.3 INDIA 87
7 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT 88
7.1 INTRODUCTION 89
TABLE 11 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 89
TABLE 12 PHARMACEUTICAL EXCIPIENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 89
7.2 ORGANIC CHEMICALS 90
TABLE 13 ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 90
TABLE 14 ORGANIC CHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
7.2.1 OLEOCHEMICALS 91
TABLE 15 OLEOCHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 91
TABLE 16 OLEOCHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 91
7.2.1.1 Fatty alcohols 92
7.2.1.1.1 Fatty alcohols are widely used as nonionic surfactants due to their amphipathic nature—a major driver for market growth 92
TABLE 17 FATTY ALCOHOLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 92
7.2.1.2 Mineral stearates 93
7.2.1.2.1 Wide use of magnesium stearates as excipients in nutraceutical and pharmaceutical formulations to drive market growth 93
TABLE 18 MINERAL STEARATES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
7.2.1.3 Glycerin 94
7.2.1.3.1 Extensive applications of glycerin to drive market growth 94
TABLE 19 GLYCERIN MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
7.2.1.4 Other oleochemicals 95
TABLE 20 OTHER OLEOCHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
7.2.2 CARBOHYDRATES 96
TABLE 21 CARBOHYDRATES MARKET, BY TYPE, 2019–2026 (USD MILLION) 96
TABLE 22 CARBOHYDRATES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 96
7.2.2.1 Sugars 97
TABLE 23 SUGARS MARKET, BY TYPE, 2019–2026 (USD MILLION) 97
TABLE 24 SUGARS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 97
7.2.2.1.1 Actual sugars 98
TABLE 25 ACTUAL SUGARS MARKET, BY TYPE, 2019–2026 (USD MILLION) 98
TABLE 26 ACTUAL SUGARS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 98
7.2.2.1.1.1 Lactose 99
7.2.2.1.1.1.1 Lactose is the most commonly used excipient in tablets and capsules 99
7.2.2.1.1.2 Sucrose 99
7.2.2.1.1.2.1 Sucrose is extensively used in oral pharmaceutical formulations 99
7.2.2.1.1.3 Dextrose (D-Glucose) 99
7.2.2.1.1.3.1 Dextrose has a wide range of applications in tablets and capsules 99
7.2.2.1.2 Sugar alcohols 99
TABLE 27 SUGAR ALCOHOLS MARKET, BY TYPE, 2019–2026 (USD MILLION) 100
TABLE 28 SUGAR ALCOHOLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 100
7.2.2.1.2.1 Mannitol 101
7.2.2.1.2.1.1 Mannitol is widely used with moisture-sensitive active ingredients as it is non-hygroscopic in nature 101
7.2.2.1.2.2 Sorbitol 101
7.2.2.1.2.2.1 Sorbitol is one of the most widely used compression diluents for pharmaceutical formulations 101
7.2.2.1.2.3 Other sugar alcohols 101
7.2.2.1.3 Artificial sweeteners 101
7.2.2.1.3.1 Aspartame is the most commonly used artificial sweetener 101
TABLE 29 ARTIFICIAL SWEETENERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 102
7.2.2.2 Cellulose 102
TABLE 30 CELLULOSE MARKET, BY TYPE, 2019–2026 (USD MILLION) 103
TABLE 31 CELLULOSE MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 103
7.2.2.2.1 Microcrystalline cellulose 104
7.2.2.2.1.1 Microcrystalline cellulose is the most widely used excipient in the direct compression method for tablets 104
TABLE 32 MICROCRYSTALLINE CELLULOSE MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 104
7.2.2.2.2 Cellulose ethers 105
7.2.2.2.2.1 Cellulose ethers are effective even at a lower concentration 105
TABLE 33 CELLULOSE ETHERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
7.2.2.2.3 CMC and croscarmellose sodium 106
7.2.2.2.3.1 Multiple advantages of CMC and croscarmellose sodium make them the most widely used suspending agents in injectable preparations 106

TABLE 34 CMC & CROSCARMELLOSE SODIUM MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 106
7.2.2.2.4 Cellulose esters 107
7.2.2.2.4.1 Cellulose esters enable the delivery of drugs in cellular membranes and the intracellular matrix 107
TABLE 35 CELLULOSE ESTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 107
7.2.2.3 Starch 107
TABLE 36 STARCH MARKET, BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 37 STARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
7.2.2.3.1 Modified starch 109
7.2.2.3.1.1 Modified starch is widely used in sustained-release tablets due to its cold-water swelling and gel barrier formation capabilities 109
TABLE 38 MODIFIED STARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 109
7.2.2.3.2 Dried starch 110
7.2.2.3.2.1 Dried starch is a strong binding and coating agent 110
TABLE 39 DRIED STARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 110
7.2.2.3.3 Converted starch 110
7.2.2.3.3.1 Converted starch is used as a molecular encapsulation agent and offers enhanced solubility and stability for drugs 110
TABLE 40 CONVERTED STARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 111
7.2.3 PETROCHEMICALS 111
TABLE 41 PETROCHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 112
TABLE 42 PETROCHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 112
7.2.3.1 Glycols 113
TABLE 43 GLYCOLS MARKET, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 44 GLYCOLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 113
7.2.3.1.1 Polyethylene glycol 114
7.2.3.1.1.1 PEG is the excipient of choice in a large number of drug formulations due to its tunable properties and well-established safety profile 114
7.2.3.1.2 Propylene glycol 114
7.2.3.1.2.1 In high amounts, propylene glycol has been reported to be toxic among the pediatric population 114
7.2.3.2 Povidones 114
7.2.3.2.1 Rising demand for fast-dissolving tablets is expected to propel the growth of this segment 114
TABLE 45 POVIDONES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 115
7.2.3.3 Mineral hydrocarbons 115
TABLE 46 MINERAL HYDROCARBONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 115
TABLE 47 MINERAL HYDROCARBONS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 116
7.2.3.3.1 Petrolatum 116
7.2.3.3.1.1 Petrolatum is commonly used in topical formulations 116
7.2.3.3.2 Mineral waxes 116
7.2.3.3.2.1 Mineral waxes are non-toxic and non-irritant in nature and are suitable for skin and eye preparations 116
7.2.3.3.3 Mineral oils 117
7.2.3.3.3.1 White mineral oils are good emollients, lubricating agents, and solvents 117
7.2.3.4 Acrylic polymers 117
7.2.3.4.1 Wide use of acrylic polymers in controlled-release drug formulations to drive market growth 117
TABLE 48 ACRYLIC POLYMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 117
7.2.3.5 Other petrochemicals 118
TABLE 49 OTHER PETROCHEMICALS MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 118
7.2.4 PROTEINS 118
7.2.4.1 Growing applications of proteins as carriers for microparticles and nanoparticles to drive market growth 118
TABLE 50 PROTEINS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 119
7.2.5 OTHER ORGANIC CHEMICALS 119
TABLE 51 OTHER ORGANIC CHEMICALS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 120
7.3 INORGANIC CHEMICALS 120
TABLE 52 INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 121
TABLE 53 INORGANIC CHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 121
7.3.1 CALCIUM PHOSPHATE 122
7.3.1.1 Chemical purity and low incompatibility with drugs aid their high usage in the pharmaceutical industry 122
TABLE 54 CALCIUM PHOSPHATE MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
7.3.2 METAL OXIDES 123
7.3.2.1 Availability of silicon oxides in the hydrophobic, hydrophilic, and granulated forms to aid market growth 123
TABLE 55 METAL OXIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 123
7.3.3 HALITES 124
7.3.3.1 Increased utilization of halites in vaccines and controlled-release formulations is driving their demand in the market 124
TABLE 56 HALITES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 124
7.3.4 CALCIUM CARBONATE 125
7.3.4.1 Properties such as short disintegration time and excellent mechanical strength for oral dosage formulations to drive the market 125
TABLE 57 CALCIUM CARBONATE MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 125
7.3.5 CALCIUM SULFATE 126
7.3.5.1 Calcium sulfate is a cost-effective, quality-enhancing diluent for solid dosage forms 126
TABLE 58 CALCIUM SULFATE MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 126
7.3.6 OTHER INORGANIC CHEMICALS 126
TABLE 59 OTHER INORGANIC CHEMICALS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 127

7.4 OTHER CHEMICALS 127
TABLE 60 OTHER CHEMICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 128
8 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY 129
8.1 INTRODUCTION 130
TABLE 61 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 130
8.2 FILLERS & DILUENTS 131
8.2.1 DILUENTS OFFER PROPERTIES SUCH AS IMPROVED COHESION, DIRECT COMPRESSION, AND FLOW TO THE FINAL DOSE IN TABLETS 131
TABLE 62 PHARMACEUTICAL EXCIPIENTS MARKET FOR FILLERS & DILUENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 132
8.3 SUSPENDING & VISCOSITY AGENTS 132
8.3.1 SUSPENSIONS OFFER ADVANTAGES SUCH AS DRUG STABILITY AND TASTE MASKING 132
TABLE 63 PHARMACEUTICAL EXCIPIENTS MARKET FOR SUSPENDING & VISCOSITY AGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 133
8.4 COATING AGENTS 133
8.4.1 INCREASING USE OF SUSTAINED-RELEASE FORMULATIONS IN THE PHARMA INDUSTRY TO DRIVE MARKET GROWTH 133
TABLE 64 PHARMACEUTICAL EXCIPIENTS MARKET FOR COATING AGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 134
8.5 BINDERS 134
8.5.1 BINDERS PROVIDE THE PROPERTIES OF FLUIDITY AND COMPRESSIBILITY ESSENTIAL FOR TABLET MANUFACTURING 134
TABLE 65 PHARMACEUTICAL EXCIPIENTS MARKET FOR BINDERS, BY COUNTRY,
2019–2026 (USD MILLION) 135
8.6 FLAVORING AGENTS & SWEETENERS 135
8.6.1 FLAVORING AGENTS ARE USED TO IMPROVE THE PALATABILITY OF DRUGS 135
TABLE 66 PHARMACEUTICAL EXCIPIENTS MARKET FOR FLAVORING AGENTS & SWEETENERS, BY COUNTRY, 2019–2026 (USD MILLION) 136
8.7 DISINTEGRANTS 136
8.7.1 DISINTEGRANTS ARE FORMULATED TO CAUSE A RAPID BREAK-UP OF SOLIDS DOSAGE FORMS 136
TABLE 67 PHARMACEUTICAL EXCIPIENTS MARKET FOR DISINTEGRANTS, BY COUNTRY, 2019–2026 (USD MILLION) 137
8.8 COLORANTS 137
8.8.1 COLORING AGENTS ARE USED IN HARD AND SOFT GELATIN CAPSULES, TABLETS, ORAL LIQUIDS, AND TOPICAL CREAMS 137
TABLE 68 PHARMACEUTICAL EXCIPIENTS MARKET FOR COLORANTS, BY COUNTRY, 2019–2026 (USD MILLION) 138
8.9 LUBRICANTS & GLIDANTS 138
8.9.1 GLIDANTS IMPROVE THE FLOW PROPERTIES OF A FORMULATION BY REDUCING INTER-PARTICLE FRICTION AND COHESION 138
TABLE 69 PHARMACEUTICAL EXCIPIENTS MARKET FOR LUBRICANTS & GLIDANTS, BY COUNTRY, 2019–2026 (USD MILLION) 139

8.10 PRESERVATIVES 139
8.10.1 BENZYL ALCOHOL IS A WIDELY USED PRESERVATIVE IN THE PHARMACEUTICAL AND NUTRACEUTICAL INDUSTRY 139
TABLE 70 PHARMACEUTICAL EXCIPIENTS MARKET FOR PRESERVATIVES, BY COUNTRY, 2019–2026 (USD MILLION) 140
8.11 EMULSIFYING AGENTS 140
8.11.1 USE OF SOLUBILITY ENHANCEMENT EXCIPIENTS IN LIQUID DRUG FORMULATIONS HELPS INCREASE API BIOAVAILABILITY 140
TABLE 71 PHARMACEUTICAL EXCIPIENTS MARKET FOR EMULSIFYING AGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 141
8.12 OTHER FUNCTIONALITIES 142
TABLE 72 OTHER FUNCTIONALITIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 142
9 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION 143
9.1 INTRODUCTION 144
TABLE 73 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 144
9.2 ORAL FORMULATIONS 144
TABLE 74 PHARMACEUTICAL EXCIPIENTS MARKET FOR ORAL FORMULATIONS,
BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 75 PHARMACEUTICAL EXCIPIENTS MARKET FOR ORAL FORMULATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 145
9.2.1 TABLETS 146
9.2.1.1 Tablets are the most widely used dosage forms 146
TABLE 76 TYPICAL COMPOSITION OF TABLETS 146
TABLE 77 PHARMACEUTICAL EXCIPIENTS MARKET FOR TABLETS, BY COUNTRY,
2019–2026 (USD MILLION) 147
9.2.2 CAPSULES 147
TABLE 78 PHARMACEUTICAL EXCIPIENTS MARKET FOR CAPSULES, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 79 PHARMACEUTICAL EXCIPIENTS MARKET FOR CAPSULES, BY COUNTRY, 2019–2026 (USD MILLION) 148
9.2.2.1 Hard gelatin capsules 149
9.2.2.1.1 Ease of manufacturing and versatility are driving the growth of the hard gelatin capsules market 149
TABLE 80 PHARMACEUTICAL EXCIPIENTS MARKET FOR HARD GELATIN CAPSULES,
BY COUNTRY, 2019–2026 (USD MILLION) 149
9.2.2.2 Soft gelatin capsules 150
9.2.2.2.1 Stability concerns with highly water-soluble compounds and compounds susceptible to hydrolysis have restricted market growth 150
TABLE 81 PHARMACEUTICAL EXCIPIENTS MARKET FOR SOFT GELATIN CAPSULES,
BY COUNTRY, 2019–2026 (USD MILLION) 150
9.2.3 LIQUID FORMULATIONS 151
9.2.3.1 Liquid formulations require no dissolution time and boast faster absorption from the stomach than tablets 151
TABLE 82 PHARMACEUTICAL EXCIPIENTS MARKET FOR LIQUID FORMULATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 151
9.3 TOPICAL FORMULATIONS 152
9.3.1 ADVANTAGES OF TOPICAL DRUG DELIVERY ARE DRIVING THE DEMAND FOR EXCIPIENTS IN THIS SEGMENT 152
TABLE 83 PHARMACEUTICAL EXCIPIENTS MARKET FOR TOPICAL FORMULATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 153
9.4 PARENTERAL FORMULATIONS 153
9.4.1 EMERGENCE OF NEW BIOLOGICAL MOLECULES TO INCREASE THE DEMAND FOR EXCIPIENTS 153
TABLE 84 TYPICAL COMPOSITION OF PARENTERAL FORMULATIONS 154
TABLE 85 EXCIPIENTS USED IN PARENTERAL FORMULATIONS 154
TABLE 86 PHARMACEUTICAL EXCIPIENTS MARKET FOR PARENTERAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 155
9.5 OTHER FORMULATIONS 156
TABLE 87 PHARMACEUTICAL EXCIPIENTS MARKET FOR OTHER FORMULATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 156
10 PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION 157
10.1 INTRODUCTION 158
TABLE 88 PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION,
2019–2026 (USD MILLION) 158
10.2 EUROPE 159
10.2.1 COVID-19 IMPACT ON THE EUROPEAN MARKET 159
FIGURE 30 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT 160
TABLE 89 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 161
TABLE 90 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 161
TABLE 91 EUROPE: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 161
TABLE 92 EUROPE: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 162
TABLE 93 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION) 162
TABLE 94 EUROPE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 163
10.2.2 GERMANY 163
10.2.2.1 Germany accounted for the largest share of the European pharmaceutical excipients market in 2020 163
TABLE 95 GERMANY: KEY MICROINDICATORS 164
TABLE 96 GERMANY: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 164
TABLE 97 GERMANY: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 164
TABLE 98 GERMANY: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 99 GERMANY: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION) 165
TABLE 100 GERMANY: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION) 166
10.2.3 FRANCE 166
10.2.3.1 Large geriatric population in the country to support market growth 166
TABLE 101 FRANCE: KEY MICROINDICATORS 167
TABLE 102 FRANCE: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 167
TABLE 103 FRANCE: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 104 FRANCE: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 168
TABLE 105 FRANCE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION) 168
TABLE 106 FRANCE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 169
10.2.4 UK 169
10.2.4.1 Growing adoption of generics and the development of novel multi-functional, co-processed excipients to drive market growth 169
TABLE 107 UK: KEY MICROINDICATORS 170
TABLE 108 UK: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 170
TABLE 109 UK: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 170
TABLE 110 UK: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 111 UK: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 171
TABLE 112 UK: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 172
10.2.5 SWITZERLAND 172
10.2.5.1 Large volume of pharmaceuticals produced in Switzerland is a key factor driving market growth 172
TABLE 113 SWITZERLAND: KEY MICROINDICATORS 172
TABLE 114 SWITZERLAND: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 173
TABLE 115 SWITZERLAND: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 173
TABLE 116 SWITZERLAND: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 173
TABLE 117 SWITZERLAND: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION) 174
TABLE 118 SWITZERLAND: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION) 174
10.2.6 ITALY 175
10.2.6.1 Budgetary constraints and restricted healthcare spending to impede the growth of the Italian market 175

TABLE 119 ITALY: KEY MICROINDICATORS 175
TABLE 120 ITALY: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 175
TABLE 121 ITALY: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 176
TABLE 122 ITALY: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 176
TABLE 123 ITALY: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 177
TABLE 124 ITALY: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 177
10.2.7 SPAIN 178
10.2.7.1 High consumption of biologics to support market growth 178
TABLE 125 SPAIN: KEY MICROINDICATORS 178
TABLE 126 SPAIN: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 178
TABLE 127 SPAIN: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 128 SPAIN: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 179
TABLE 129 SPAIN: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 179
TABLE 130 SPAIN: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 180
10.2.8 REST OF EUROPE 180
TABLE 131 ROE: PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 181
TABLE 132 ROE: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 181
TABLE 133 ROE: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 181
TABLE 134 ROE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 182
TABLE 135 ROE: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 182
10.3 NORTH AMERICA 183
10.3.1 COVID-19 IMPACT ON THE NORTH AMERICAN MARKET 183
FIGURE 31 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT 184
TABLE 136 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 185
TABLE 137 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 185
TABLE 138 NORTH AMERICA: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 185
TABLE 139 NORTH AMERICA: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 186
TABLE 140 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET,
BY FUNCTIONALITY, 2019–2026 (USD MILLION) 186
TABLE 141 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET,
BY FORMULATION, 2019–2026 (USD MILLION) 187
10.3.2 US 187
10.3.2.1 The US dominates the North American market due to the increasing use of biologics and the increasing per capita pharmaceutical spending 187
TABLE 142 US: KEY MICROINDICATORS 188
TABLE 143 US: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 188
TABLE 144 US: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 188
TABLE 145 US: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 189
TABLE 146 US: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 189
TABLE 147 US: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 190
10.3.3 CANADA 190
10.3.3.1 Strong growth of the emerging markets and slowdown in new product approvals to hamper the market growth in Canada 190
TABLE 148 CANADA: KEY MICROINDICATORS 190
TABLE 149 CANADA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 191
TABLE 150 CANADA: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 191
TABLE 151 CANADA: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 191
TABLE 152 CANADA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION) 192
TABLE 153 CANADA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 192
10.4 ASIA PACIFIC 193
10.4.1 COVID-19 IMPACT ON THE APAC MARKET 193
FIGURE 32 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT 194
TABLE 154 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 195
TABLE 155 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 195
TABLE 156 ASIA PACIFIC: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 195
TABLE 157 ASIA PACIFIC: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 196
TABLE 158 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION) 196
TABLE 159 ASIA PACIFIC: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION) 197
10.4.2 JAPAN 197
10.4.2.1 The rapid growth of Japan’s geriatric population will greatly drive the demand for pharmaceuticals 197
TABLE 160 JAPAN: KEY MICROINDICATORS 198
TABLE 161 JAPAN: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 198
TABLE 162 JAPAN: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 198
TABLE 163 JAPAN: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 199
TABLE 164 JAPAN: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 199
TABLE 165 JAPAN: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 200
10.4.3 CHINA 200
10.4.3.1 Emphasis on generics and off-patent drugs to drive the market in China 200
TABLE 166 CHINA: KEY MICROINDICATORS 201
TABLE 167 CHINA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 201
TABLE 168 CHINA: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 201
TABLE 169 CHINA: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 202
TABLE 170 CHINA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 202
TABLE 171 CHINA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 203
10.4.4 INDIA 203
10.4.4.1 India is a leading producer of generics 203
TABLE 172 INDIA: KEY MICROINDICATORS 204
TABLE 173 INDIA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 204
TABLE 174 INDIA: ORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 204
TABLE 175 INDIA: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 205
TABLE 176 INDIA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY,
2019–2026 (USD MILLION) 205
TABLE 177 INDIA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 206
10.4.5 SOUTH KOREA 206
10.4.5.1 Thriving generic drug market to support the growth of pharmaceutical excipients market in South Korea 206
TABLE 178 SOUTH KOREA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 207
TABLE 179 SOUTH KOREA: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 207
TABLE 180 SOUTH KOREA: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 207
TABLE 181 SOUTH KOREA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION) 208
TABLE 182 SOUTH KOREA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION) 208
10.4.6 REST OF ASIA PACIFIC 208
TABLE 183 ROAPAC: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 209
TABLE 184 ROAPAC: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 209
TABLE 185 ROAPAC: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 210
TABLE 186 ROAPAC: PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2019–2026 (USD MILLION) 210
TABLE 187 ROAPAC: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION,
2019–2026 (USD MILLION) 211
10.5 LATIN AMERICA 211
10.5.1 GROWING GERIATRIC POPULATION AND DISEASE PREVALENCE ARE DRIVING MARKET GROWTH 211
10.5.2 COVID-19 IMPACT ON THE LATAM MARKET 212
TABLE 188 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 212
TABLE 189 LATIN AMERICA: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 212
TABLE 190 LATIN AMERICA: INORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 213
TABLE 191 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET,
BY FUNCTIONALITY, 2019–2026 (USD MILLION) 213
TABLE 192 LATIN AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION) 214
10.6 MIDDLE EAST AND AFRICA 214
10.6.1 UNSATURATED MARKETS IN THE REGION HAVE DRAWN THE ATTENTION
OF GLOBAL PLAYERS 214
10.6.2 COVID-19 IMPACT ON THE MEA MARKET 215
TABLE 193 MIDDLE EAST AND AFRICA: PHARMACEUTICAL EXCIPIENTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 215
TABLE 194 MIDDLE EAST AND AFRICA: ORGANIC CHEMICALS MARKET, BY TYPE,
2019–2026 (USD MILLION) 215
TABLE 195 MIDDLE EAST AND AFRICA: INORGANIC CHEMICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 216
TABLE 196 MIDDLE EAST AND AFRICA: PHARMACEUTICAL EXCIPIENTS MARKET,
BY FUNCTIONALITY, 2019–2026 (USD MILLION) 216
TABLE 197 MIDDLE EAST AND AFRICA: PHARMACEUTICAL EXCIPIENTS MARKET,
BY FORMULATION, 2019–2026 (USD MILLION) 217
11 COMPETITIVE LANDSCAPE 218
11.1 INTRODUCTION 218
FIGURE 33 KEY PLAYER STRATEGIES 218
11.2 COMPANY GEOGRAPHIC FOOTPRINT: PHARMACEUTICAL EXCIPIENTS MARKET 219
FIGURE 34 COMPANY GEOGRAPHIC FOOTPRINT: PHARMACEUTICAL EXCIPIENTS MARKET (2020) 219
11.3 COMPETITIVE LEADERSHIP MAPPING 220
11.3.1 STARS 220
11.3.2 EMERGING LEADERS 220
11.3.3 PERVASIVE PLAYERS 220
11.3.4 PARTICIPANTS 221
FIGURE 35 PHARMACEUTICAL EXCIPIENTS MARKET: COMPETITIVE LEADERSHIP MAPPING (2019) 221
11.4 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020) 222
11.4.1 PROGRESSIVE COMPANIES 222
11.4.2 DYNAMIC COMPANIES 222
11.4.3 STARTING BLOCKS 222
11.4.4 RESPONSIVE COMPANIES 222
FIGURE 36 PHARMACEUTICAL EXCIPIENTS MARKET: START-UP COMPANY EVALUATION MATRIX (2020) 223
11.5 MARKET SHARE ANALYSIS 224
FIGURE 37 PHARMACEUTICAL EXCIPIENTS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020 224
11.6 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 225
FIGURE 38 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE PHARMACEUTICAL EXCIPIENTS MARKET 226
11.7 PRODUCT FOOTPRINT 226
11.8 COMPETITIVE SITUATIONS AND TRENDS 227
TABLE 198 PRODUCT LAUNCHES (2017-2020) 227
TABLE 199 MERGERS & ACQUISITIONS (2017-2020) 228
TABLE 200 AGREEMENTS & PARTNERSHIPS (2017-2020) 229
TABLE 201 EXPANSIONS (2017-2020) 229
TABLE 202 OTHER DEVELOPMENTS (2017-2020) 230

12 COMPANY PROFILES 231
12.1 KEY PLAYERS 231
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1.1 DUPONT DE NEMOURS, INC. 231
TABLE 203 DUPONT DE NEMOURS: BUSINESS OVERVIEW 231
FIGURE 39 DUPONT DE NEMOURS, INC.: COMPANY SNAPSHOT (2019) 232
12.1.2 ROQUETTE FRÈRES 237
TABLE 204 ROQUETTE FRÈRES: BUSINESS OVERVIEW 237
12.1.3 ASHLAND 242
TABLE 205 ASHLAND: BUSINESS OVERVIEW 242
FIGURE 40 ASHLAND: COMPANY SNAPSHOT (2020) 243
12.1.4 EVONIK INDUSTRIES AG 248
TABLE 206 EVONIK INDUSTRIES: BUSINESS OVERVIEW 248
FIGURE 41 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2019) 249
12.1.5 BASF SE 253
TABLE 207 BASF SE: BUSINESS OVERVIEW 253
FIGURE 42 BASF SE: COMPANY SNAPSHOT (2019) 253
12.1.6 KERRY GROUP PLC 259
TABLE 208 KERRY GROUP: BUSINESS OVERVIEW 259
FIGURE 43 KERRY GROUP PLC: COMPANY SNAPSHOT (2019) 260
12.2 OTHER PLAYERS 262
12.2.1 CRODA INTERNATIONAL 262
TABLE 209 CRODA INTERNATIONAL: BUSINESS OVERVIEW 262
FIGURE 44 CRODA INTERNATIONAL: COMPANY SNAPSHOT (2019) 263
12.2.2 ASSOCIATED BRITISH FOODS PLC 267
TABLE 210 ASSOCIATED BRITISH FOODS PLC: BUSINESS OVERVIEW 267
FIGURE 45 ASSOCIATED BRITISH FOODS PLC: COMPANY SNAPSHOT (2020) 267
12.2.3 ARCHER DANIELS MIDLAND COMPANY 271
TABLE 211 ARCHER DANIELS MIDLAND: BUSINESS OVERVIEW 271
FIGURE 46 ARCHER DANIELS MIDLAND COMPANY: COMPANY SNAPSHOT (2019) 272
12.2.4 LUBRIZOL CORPORATION 274
TABLE 212 LUBRIZOL CORPORATION: BUSINESS OVERVIEW 274
12.2.5 INNOPHOS HOLDINGS, INC. 277
TABLE 213 INNOPHOS HOLDINGS: BUSINESS OVERVIEW 277
FIGURE 47 INNOPHOS HOLDINGS, INC.: COMPANY SNAPSHOT (2019) 278
12.2.6 WACKER CHEMIE AG 280
TABLE 214 WACKER CHEMIE AG: BUSINESS OVERVIEW 280
FIGURE 48 WACKER CHEMIE AG: COMPANY SNAPSHOT (2019) 281
12.2.7 AIR LIQUIDE S.A. 283
TABLE 215 AIR LIQUIDE: BUSINESS OVERVIEW 283
FIGURE 49 AIR LIQUIDE S.A.: COMPANY SNAPSHOT (2019) 283
12.2.8 COLORCON, INC. 286
TABLE 216 COLORCON, INC.: BUSINESS OVERVIEW 286
12.2.9 DMV-FONTERRA EXCIPIENTS GMBH & CO. KG 289
TABLE 217 DMV-FONTERRA EXCIPIENTS GMBH & CO. KG.: BUSINESS OVERVIEW 289
12.2.10 JRS PHARMA GMBH & CO. KG 290
TABLE 218 JRS PHARMA GMBH & CO. KG.: BUSINESS OVERVIEW 290
12.2.11 MERCK KGAA 292
TABLE 219 MERCK KGAA.: BUSINESS OVERVIEW 292
FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2019) 292
12.2.12 DOW CHEMICALS 294
TABLE 220 DOW CHEMICALS: BUSINESS OVERVIEW 294
FIGURE 51 DOW CHEMICALS: COMPANY SNAPSHOT (2019) 294
12.2.13 FINAR LIMITED 295
12.2.14 MEGGLE EXCIPIENTS & TECHNOLOGY 295
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX 296
13.1 INDUSTRY SPEAKS 296
13.2 DISCUSSION GUIDE 297
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 301
13.4 AUTHOR DETAILS 303

★調査レポート[世界の医薬品添加剤市場予測:製品別、機能性別、製剤別] ( Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates [Sugar (Dextrose)], Inorganic Chemicals), Functionality (Fillers, Diluents, Coating, Disintegrants), Formulation (Tablet, Capsule, Topical, Parenteral) - Global Forecast to 2026 / PH3047) 販売に関する免責事項
[世界の医薬品添加剤市場予測:製品別、機能性別、製剤別] ( Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates [Sugar (Dextrose)], Inorganic Chemicals), Functionality (Fillers, Diluents, Coating, Disintegrants), Formulation (Tablet, Capsule, Topical, Parenteral) - Global Forecast to 2026 / PH3047) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆